Independent safety monitors recommended stopping a phase 3 clinical trial early due to “overwhelming evidence of efficacy” after finding a new drug, sabizabulin, cut the death rate among severe COVID-19 patients by 55 percent, the drug’s developer, Veru, announced April 11.
Read the full post on Becker's Hospital Review - Healthcare News
